MA-GILLETTE
31.5.2023 15:31:33 CEST | Business Wire | Press release
Gillette (NYSE: PG), the world’s largest male grooming company and brand pioneer in gaming and esports, proudly announced the return of the highly anticipated Gillette Cup Featuring Fortnite, a two-day international gaming competition featuring a custom-built island in Fortnite. First played in February 2022, the inaugural Gillette Cup garnered over 300,000 viewing hours throughout the tournament. Back for its second year, the event kicks off on June 1, 2023, and will unite members of the Gillette Gaming Alliance as they compete against members of the global Fortnite community for $50,000 -- doubling the prize pool from last year. The Gillette Cup Featuring Fortnite is among one of the largest branded tournaments to date for the gaming community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005178/en/
Gillette celebrates return of Gillette Cup Featuring Fortnite with all-star Gillette Gaming Alliance. (Photo: Business Wire)
The competition will be played on a revamped “Gillette Face-Off” island, a custom environment developed using Fortnite’s Creative toolset; this builds on the success of the island’s existing futuristic lab and mineshaft versions, which were first introduced in 2022. The custom branded Fortnite islands feature action-packed “Zero Build” gameplay and iconic Gillette products for a gaming experience as satisfying as a close shave. To compete in the “Gillette Face-Off” islands at any time, use island code 6674-8139-7577.
“The celebrated return of the Gillette Cup Featuring Fortnite is testament to our previous successes and deepening relationship with Gillette Gaming Alliance members to provide meaningful and impactful experiences to the gaming community,” explains Daniel Ordonez, Gillette Global Brand Franchise Leader. “We are looking forward to cheering on our Alliance members and engaging with Fortnite’s community – while, most importantly, meeting them where they thrive in a truly fun and authentic way.”
For the first time, viewers and fans worldwide can visit www.GilletteCup.com to check out the leaderboard and tune-in for real-time updates. Additionally, they will have the chance to win exclusive Gillette Gaming gear and products by visiting the newly launched website throughout the tournament.
Tournament Details – Competitive, Professional Sporting Event Style Format
The tournament will kick off with the Regionals Round, where eight (8) teams of “Duos,” representing eight (8) countries/regions will compete – totaling 64 teams and 128 players across the globe. Participants will represent Brazil, France, Germany, Italy, Mexico, Spain, United Kingdom, and USA/Canada. Using a points system, teams will be randomly placed on the “Gillette Face-Off” island and compete in multiple rounds of Zero Build matches.
The top 16 teams from Regionals will compete for the opportunity to advance to Semi-Finals and be divided into two (2) groups of eight (8) Duos. These 16 teams will continue to compete in multiple rounds of the “Gillette Face-Off” island. The top four (4) Duos from each group will advance to the Finals to form a single lobby and compete in multiple rounds of the Gillette Cup custom island. The Duos will be scored using the points system and awarded cash prizing, based on how they rank. The last Duo standing will be named winner of the Gillette Cup!
Gillette Gaming Alliance members – inclusive of TypicalGamer (USA/Canada), Vicens (Spain), Agustin (Spain), Papaplatte (Germany), Rumathra (Germany), Elded (Mexico), Jolavanille (France), Pizfn (Italy), Xuider (Italy), Mongraal (United Kingdom), and Nobru (Brazil) – will represent their respective countries as they battle it out against fellow professional members of the Fortnite community to bring home the “win” and championship prize.
“I have had a blast streaming for the Gillette Gaming Alliance this year and providing awesome content and experiences to my community on behalf of the brand,” shares Fortnite pro Andre Rebelo, also known as TypicalGamer, Gillette Gaming Alliance member representing North America. “I remember tuning into the Gillette Cup last year and thinking it was epic. So, I am really excited to be a part of it myself this year – and I hope to bring home the W for my fans and followers.”
The Gillette Gaming Alliance, now in its fifth year, serves as Gillette’s longest running gaming activation as well as one of the most defining and successful programs to date for the brand.
*This is an independently created Fortnite Creative experience and is not sponsored, endorsed, or administered by Epic Games, Inc.
About Gillette
For more than 120 years, Gillette has delivered precision technology and unrivaled product performance – improving the lives of over 800 million consumers around the world. From shaving and body grooming, to skin care and sweat protection, Gillette offers a wide variety of products including razors, shave gel (gels, foams and creams), skin care, after shaves, antiperspirants, deodorants and body wash. For more information and the latest news on Gillette, visit www.gillette.com. To see our full selection of products, visit www.gillette.com. Follow Gillette on Twitter, Facebook and Instagram.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper® The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005178/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom